Skip to Content
Merck
CN
  • Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin.

Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin.

Transplant infectious disease : an official journal of the Transplantation Society (2009-01-16)
P Lichtenberger, I Rosa-Cunha, M Morris, S Nishida, E Akpinar, J Gaitan, A Tzakis, S Doblecki-Lewis
ABSTRACT

Severe strongyloidiasis, including hyperinfection and dissemination, is a recognized complication of solid organ transplantation. However, the development of strongyloidiasis in a liver transplant recipient has not been previously described. We present a case of severe strongyloidiasis occurring in a patient 4 months after liver transplantation and 1 month after receiving treatment for acute rejection. We assess the management challenges in this patient who remained symptomatic despite oral treatment with ivermectin and albendazole and eventual successful treatment with parenteral ivermectin. We review the published experience with alternative methods of ivermectin administration. We also investigate the possible source of infection, as the patient was not from an endemic area.

MATERIALS
Product Number
Brand
Product Description

Ivermectin, European Pharmacopoeia (EP) Reference Standard